Free Trial

Shore Capital Forecasts Strong Price Appreciation for Genus (LON:GNS) Stock

Genus logo with Medical background

Key Points

  • Shore Capital has increased the price target for Genus (LON:GNS) from GBX 2,630 to GBX 2,900, indicating a potential upside of 7.17% from its current price.
  • Deutsche Bank also raised its price target for Genus to GBX 2,550, maintaining a "buy" rating on the stock.
  • Genus has a current market cap of £1.77 billion, and operates in animal genetics across multiple global regions.
  • Want stock alerts on Genus? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Genus (LON:GNS - Get Free Report) had its target price hoisted by equities researchers at Shore Capital from GBX 2,630 to GBX 2,900 in a research note issued to investors on Thursday, Marketbeat reports. The firm currently has a "buy" rating on the stock. Shore Capital's target price points to a potential upside of 7.81% from the stock's current price.

Separately, Deutsche Bank Aktiengesellschaft increased their price target on Genus from GBX 2,250 to GBX 2,550 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Genus presently has an average rating of "Buy" and a consensus price target of GBX 2,725.

Check Out Our Latest Research Report on Genus

Genus Stock Down 0.9%

Shares of GNS stock traded down GBX 25 during trading on Thursday, reaching GBX 2,690. The company's stock had a trading volume of 97,259 shares, compared to its average volume of 225,212. The business has a fifty day moving average price of GBX 2,317.70 and a 200-day moving average price of GBX 2,029.96. The company has a quick ratio of 1.08, a current ratio of 1.80 and a debt-to-equity ratio of 53.12. The company has a market cap of £1.76 billion, a price-to-earnings ratio of 222.98, a price-to-earnings-growth ratio of 2.87 and a beta of 0.37. Genus has a one year low of GBX 1,424 and a one year high of GBX 2,760.

About Genus

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.

Read More

Should You Invest $1,000 in Genus Right Now?

Before you consider Genus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.

While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 High Short Interest Stocks to Buy Before November
HUGE Upside Ahead: The Fastest Growing ETFs in the Market
Next Tech Boom: AI Robots Are Coming Sooner Than You Think!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines